AMWL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
American Well Corp (AMWL) is not a good buy for a beginner investor with a long-term focus at this time. The company faces significant revenue decline, weak financial performance, and cautious market sentiment. Despite some positive news around AI-driven digital healthcare platforms, the overall outlook remains negative, and analysts have lowered price targets.
The MACD is positive and expanding, indicating slight bullish momentum. However, RSI is neutral at 70.473, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (5.841), with resistance at 6.46 and support at 5.222.
Investor optimism around AI-driven digital healthcare platforms and a recent 13.3% stock price increase due to exceeding Q4 sales estimates.
Revenue guidance for 2026 is $40M below consensus, with a 20% revenue decline expected. Analysts have lowered price targets, and the company reported significant YoY declines in revenue (-22.11%), net income (-41.57%), and EPS (-45.13%).
In Q4 2025, revenue dropped to $55.31M (-22.11% YoY), net income fell to -$24.92M (-41.57% YoY), and EPS declined to -1.52 (-45.13% YoY). Gross margin also decreased to 36.06% (-2.96% YoY).
Analysts from Stifel and TD Cowen have lowered price targets to $5 and maintain Hold ratings. Concerns include a 20% revenue decline guidance and strategic restructuring, despite a solid Q4 EBITDA beat.
